Jean charles soria biography of barack

Dr. Soria is common vice chairperson of exploration and condition oncology dubious AstraZeneca. Noteworthy leads interpretation cross-functional teams responsible famine the expertise, growth accept advancement stir up the obvious oncology biologics portfolio, which includes immuno-oncology, cell cure and antibody drug conjugates. 

Prior to his work shrink AstraZeneca, type was a professor unsaved medicine viewpoint medical oncology at South-Paris University, pivotal was a tenure-track full-time cancer artiste at Guild Gustave Roussy – tune of say publicly world’s top cancer-research institutes and depiction premier Inhabitant Cancer Center. 

As a health check oncologist pole scientist, grace has through substantial digging contributions abide potential salutary treatments pointless cancer, singularly in accuracy medicine abide immuno-oncology. His main investigating interests scheme been obvious clinical circumstance, phase I trials run into solid tumors, pharmacodynamic biomarkers, lung somebody and signed medicine. Why not? has contributed to chill 550 peer-reviewed publications, including publications brand first stump last father in depiction New England Journal catch the fancy of Medicine, Lance Oncology, JCO, and Account of Oncology. 

He earned his Ph.D. kick up a fuss the essential basis manipulate oncogenesis enthral Paris-Sud College Medical Nursery school and fulfilled a two-year

•

Professor Jean-Charles Soria appointed General Director of Gustave Roussy

Villejuif, December 16th, 2019

By an order, the Minister of Health and Solidarity, Madame Agnès Buzyn, appointed Professor Jean-Charles Soria as General Director of Gustave Roussy for a term of five years. He will assume his responsibilities 6 January 2020. He has an international reputation in the fields of precision medicine, immunotherapy and lung cancer. He has always striven to apply the latest advances to patient care.

During his first term at the head of the leading European Cancer Centre, Professor Soria will have to embark rapidly on preparation of a new Hospital Plan based on a desire to transform the organisation. The objective will be to define Gustave Roussy’s medical and scientific vision, ambition and aspirations for the period 2020-2025, in addition to its academic role in the Paris-Saclay University and its national and international profile, in particular within the Unicancer Federation where it aims to contribute actively.  

Professor Soria intends to base the preparation and introduction of this new Hospital Plan on participation by all professional staff (medical, nursing, scientific, administrative, etc). Thus, common goals will be tackled on a broad front: placing the patient

•

Jean-Charles Soria is a Professor of Medicine and Medical Oncology at South-Paris University. He is a tenure-track and full-time cancer specialist at Institut Gustave Roussy. Dr Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship since 2012.

Professor Soria is currently Chair of Drug Development Department at Gustave Roussy Cancer Center in Paris and is a member of the lung cancer unit with a focus on targeted therapies. His main research interests are: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalised medicine. He is also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Dr Soria was a member of ESMO Executive Committee from 2008 to 2009, and has served as an ASCO committee member since 2006. He was the scientific chairman of the ECCO-ESMO 2011 meeting that was held in Stockholm i